NEW CHEMICAL ENTITIY

we are developing an NCE; a novel pentapolymer for treating autoimmune diseases such as MS. Our U.S. patent application with respect to our pentapolymer NCE was allowed in July 2015. We have conducted preliminary pre-clinical studies of this novel pentapolymer and plan to submit an IND in 2017.